Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) announced on Wednesday that the United States Patent and Trademark Office will issue U.S. Patent No. 12,472,205 on 18 November 2025, covering key aspects of the company's breast cancer vaccine technology.

The patent protects methods for inducing an immune response to α-lactalbumin, a protein expressed in certain breast cancers, and extends the company's intellectual property protection into the mid-2040s.

Developed in collaboration with Cleveland Clinic and exclusively licensed to Anixa, the vaccine aims to stimulate the immune system to target pre-malignant and malignant cells expressing α-lactalbumin while sparing normal tissue. The approach leverages a "retired" protein absent from healthy tissue except during lactation, potentially reducing off-target effects and providing long-lasting immune protection.

Breast cancer remains the most commonly diagnosed cancer among women, with nearly 297,000 new cases projected in the US in 2025 and approximately 43,000 expected deaths. No FDA-approved vaccine currently exists for prevention, highlighting a significant unmet need.

Anixa's broader oncology portfolio includes ovarian cancer immunotherapies developed with Moffitt Cancer Center using chimeric endocrine receptor-T cell (CER-T) technology, as well as additional vaccines targeting high-incidence malignancies in lung, colon, and prostate. The company's model partners with leading research institutions to develop and commercialise innovative cancer therapies.